Search

Work participation is a goal of rehabilitation for patients at working age and has been vigorously advocated by stakeholders in and beyond the health sector. This project will study whether work ability and work status indeed do change following rehabilitation. The study is one of three work packages in a large longitudinal multicenter study (the RehabNytte study) where ≈4000 participants with different diagnoses were included at 17 rehabilitation centers across Norway and followed for one year. Linkage to register data from the Norwegian Welfare and Labour administration (NAV) for the year before and after rehabilitation enables us to identify trajectories and prognostic factors for change in work- and benefit status over time, and the rehabilitation group will also be compared to a matched control group of sick-listed patients that is drawn from register data. The follow up period, partly before and partly during the COVID-19 pandemic, also provides an opportunity to study its influence on return to work after rehabilitation.

Additional file 4:. Table S1 Demographic and clinical characteristics of patients with IFNα below or above lowest limit of detection

Additional file 2:. Figure S2. Baseline IFNα protein levels do not predict remission in any of the treatment arms. Baseline IFNα protein levels in plasma from patients with early RA stratified according to DAS28-ESR 24 weeks after treatment initiation; in remission (DAS28-ESR < 2.6), low disease activity (2.6 < DAS28-ESR ≤ 3.2) or moderate/high disease activity (DAS28-ESR > 3.2) with A) all treatments, B) methotrexate + prednisone, C) methotrexate + TNFi, D) methotrexate + CTLA-4Ig and E) methotrexate + IL-6Ri. MTX (methotrexate), TNFi (certolizumab-pegol), CTLA-4Ig (abatacept), IL-6Ri (tocilizumab). Kruskal-Wallis test followed by Dunn’s multiple comparison test.

Additional file 3:. Figure S3. IFNα protein levels at baseline do not correlate with CDAI or DAS28-ESR. Correlation between IFNα protein level in patients with levels above detection limit at day 1 and A) CDAI day 1, B) CDAI week 24, C) absolute difference in CDAI between week 24 and day 1, D) DAS28-ESR day 1, E) DAS28-ESR week 24 and F) absolute difference in DAS28-ESR between week 24 and day 1. Spearman rank correlation coefficient.

Additional file 2 : Table S1. The diagnostic performance of FOI measuring synovitis using MRI grade 2 & 3 as reference.

A complete list of current spin-off projects. (PDF 173 kb)

A completed SPIRIT Checklist. (PDF 97 kb)

OBJECTIVE: To examine the performance of ultrasound (US) for the diagnosis of gout using the presence of monosodium urate monohydrate (MSU) crystals as the gold standard. METHODS: We analyzed data from the Study for Updated Gout Classification Criteria (SUGAR), a large, multicenter observational cross-sectional study of consecutive subjects with at least 1 swollen joint who conceivably may have gout. All subjects underwent arthrocentesis; cases were subjects with confirmed MSU crystals. Rheumatologists or radiologists who were blinded with regard to the results of the MSU crystal analysis performed US on 1 or more clinically affected joints. US findings of interest were double contour sign, tophus, and snowstorm appearance. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Multivariable logistic regression models were used to examine factors associated with positive US results among subjects with gout. RESULTS: US was performed in 824 subjects (416 cases and 408 controls). The sensitivity, specificity, PPV, and NPV for the presence of any 1 of the features were 76.9%, 84.3%, 83.3%, and 78.2%, respectively. Sensitivity was higher among subjects with a disease duration of =2 years and among subjects with subcutaneous nodules on examination (suspected tophus). Associations with a positive US finding included suspected clinical tophus (odds ratio [OR] 4.77 [95% confidence interval (95% CI) 2.23-10.21]), any abnormality on plain radiography (OR 4.68 [95% CI 2.68-8.17]), and serum urate level (OR 1.31 [95% CI 1.06-1.62]). CONCLUSION: US features of MSU crystal deposition had high specificity and high PPV but more limited sensitivity for early gout. The specificity remained high in subjects with early disease and without clinical signs of tophi.